NCT02151851 - A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis | Biotech Hunter

Enrollment

430

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions

Rheumatoid Arthritis

Interventions

BIOLOGICAL

Certolizumab Pegol

"* Active substance: Certolizumab Pegol~* Pharmaceutical Form: Prefilled syringes~* Concentration: 200 mg/ml~* Route of administration: Subcutaneous injection"

DRUG

Methotrexate

"* Active substance: Methotrexate~* Pharmaceutical form: Tablet~* Concentration: Maximum dose 10 mg per week~* Route of administration: Oral"

OTHER

Placebo

"* Active substance: Placebo~* Pharmaceutical form: Prefilled syringes~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous injection"

Trial Locations (30)

Unknown

037, Baotou

001, Beijing

002, Beijing

013, Beijing

021, Beijing

025, Beijing

033, Beijing

014, Bengbu

011, Changchun

034, Changchun

017, Changsha

019, Changsha

007, Chengdu

012, Chengdu

004, Guangzhou

015, Hangzhou

008, Harbin

005, Hefei

022, Jinan

031, Kunming

028, Nanjing

009, Shanghai

018, Shanghai

020, Shanghai

030, Shanghai

038, Shijiazhuang

010, Tianjin

006, Wuhan

016, Xi'an

035, Xi'an